Minimal hepatic encephalopathy identifies patients at risk of faster cirrhosis progression

Autor: Ampuero J, Montoliu C, Simon-Talero M, Aguilera V, Millan R, Marquez C, Jover R, Rico M, Sendra C, Serra M, Romero-Gomez M
Rok vydání: 2018
Předmět:
Zdroj: JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
r-FISABIO. Repositorio Institucional de Producción Científica
instname
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
ISSN: 0815-9319
Popis: Background and AimMinimal hepatic encephalopathy (MHE) predicts poor prognosis and could reflect an advanced liver disease. We aimed to assess whether MHE could be a surrogate marker of a further liver disease. MethodsProspective multicenter study including 320 cirrhotic patients, followed for up to 5years, which were classified at baseline in compensated cirrhosis without (stage 1) and with varices (stage 2), one decompensating event (stage 3), and any second decompensating event (stage 4). Cirrhosis progression was defined by a transition towards a different stage (competing events: liver transplant due to hepatocellular carcinoma and non-liver-related death). MHE was detected by critical flicker frequency and psychometric tests. ResultsMinimal hepatic encephalopathy was diagnosed in 18.2% (57/314) of patients. Cirrhosis progression occurred in 38.1% (122/320) of patients, while liver transplant was required in 10.9% (35/320), and 19.1% (61/320) died. In competing risk regression, MHE was associated with disease progression: model 1 {subhazard ratio [sHR] 2.34 [95%confidence interval (CI) 1.58-3.46]; P=0.0001}; model 2 [sHR 2.18 (95%CI 1.43-3.33); P=0.0001]; model 3 [sHR 2.48 (95%CI 1.63-3.76); P=0.0001]. The annual incidence rate of progression was higher in MHE patients: stage 1 (19.4 vs 5.6cases per 100person-years); stage 2 (26.8 vs 15.6); stage 3 (45.7 vs 16.5); and stage 4 (40.7 vs 12.8). MHE showed a higher cumulative incidence of disease progression from the first year in decompensated and the third year in compensated cirrhosis. ConclusionMinimal hepatic encephalopathy was associated with cirrhosis progression and showed a higher cumulative and annual incidence rate of disease progression. MHE could be a surrogate marker of disease progression, irrespective of cirrhosis status, identifying patients at risk of suffering a more aggressive cirrhosis form.
Databáze: OpenAIRE
Externí odkaz: